Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial.

Shuchi Gulati McKenzie Crist Muhammed Kashif Riaz Vinita Takiar Maria A Lehn Ilaina Monroe Sarah Palackdharry Nicky Kurtzweil Roman Jandarov Nusrat Harun Trisha Michel Wise-Draper

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.

Keyphrases

clinical trial
double blind
squamous cell carcinoma
small cell lung cancer
open label
phase ii
phase iii
metastatic colorectal cancer
locally advanced
placebo controlled
wild type
study protocol
randomized controlled trial
radiation therapy